Nuvectis Pharma, Inc. (NVCT) analyst actions
Rating and price-target actions on NVCT in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the NVCT overview →
3 measured NVCT analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC | Press release | +0.00% | -1.17% | |
| Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 | Press release | +2.76% | — | |
| Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets | Press release | — | -0.45% |
Keep exploring
More NVCT: earnings → · SEC filings → · NVCT overview →